Breast cancer is a heterogeneous disease manifesting diversity at the molecular,
histological and clinical level. The development of breast cancer classification was centered …

Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …

Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10%
cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical …

Estrogen receptor (ER) status in breast cancer (BC) is determined using
immunohistochemistry (IHC) with nuclear expression in≥ 1% of cells defined as ER …

Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping
breast cancers. However, the connections between histology and multi-omics status have …

Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …

Introduction Traditionally, estrogen receptor (ER)-positive breast cancer has been defined
as tumors with≥ 1% positive for ER. The updated American Society of Clinical …

The management of patients with breast cancer (BC) relies on the assessment of a defined
set of well-established prognostic and predictive markers. Despite overlap, prognostic …

Indication for neoadjuvant chemotherapy (NACT) in HR+/HER2-negative tumors is
controversial. Pathological complete response (pCR) rates range from 0 to 18% while breast …

Over the last few years, the indication for chemotherapy use in HR+/HER2− early BC has
been significantly modified by the introduction of gene-expression profiling. In the adjuvant …